Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IM19-41BB CAR-T cells
- Development stage
- Unknown
- Lead developer
- Immunochina Pharmaceuticals
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
IM19-41BB CAR-T cells are an investigational autologous chimeric antigen receptor (CAR) T-cell therapy designed to target the CD19 antigen, which is widely expressed on B-cell malignancies. The construct features a 4-1BB (CD137) costimulatory domain, intended to promote long-term T-cell persistence and sustained anti-tumor activity. Developed by Beijing Immunochina Medical Science & Technology in collaboration with clinical sites like Beijing Boren Hospital, this therapy is primarily being studied for patients with relapsed or refractory CD19-positive aggressive non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. In clinical trials, it is often evaluated alongside or in comparison to CD28-costimulated variants to optimize safety and efficacy profiles.
- Other names
- IM19-41BB CAR-TIM-19-41BB CAR-TIM 19-41BB CAR-T
02
Targets
Beyond the preview
Go deeper on IM19-41BB CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IM19-41BB CAR-T cells.